(MDXG) MiMedx - Ratings and Ratios
Allograft, Wound, Graft, Membrane, Tissue
MDXG EPS (Earnings per Share)
MDXG Revenue
Description: MDXG MiMedx August 25, 2025
MiMedx Group Inc (NASDAQ:MDXG) is a biotechnology company listed on the NASDAQ stock exchange. The companys stock performance is characterized by a current price of $7.31, with various moving averages indicating a potential trend reversal. To assess the viability of MDXG as a trading opportunity, its essential to examine key economic drivers and KPIs.
The biotechnology industry is heavily influenced by factors such as R&D pipeline strength, regulatory approvals, and market demand for innovative treatments. MiMedxs financial health, as reflected in its market capitalization of $1.038 billion, suggests a considerable presence in the industry. The price-to-earnings ratio of 33.43 and forward P/E of 19.53 indicate that investors have certain growth expectations, which may be driven by the companys product portfolio and its ability to expand into new markets.
A critical aspect of evaluating MDXGs potential is analyzing its return on equity (RoE) of 16.22%, which signifies the companys ability to generate profits from shareholder equity. This metric, combined with the companys P/E ratio, suggests that investors are willing to pay a premium for MDXGs earnings, potentially due to growth prospects or the companys competitive positioning within the biotechnology sector.
To deconstruct MDXGs trading opportunity further, its crucial to monitor key performance indicators such as revenue growth, gross margin expansion, and the success of its product pipeline. The companys ability to navigate regulatory landscapes, particularly in the biotechnology industry, will also be a significant driver of its stock performance. By focusing on these fundamental drivers and maintaining a data-driven approach, traders can better assess the optimal entry and exit points for MDXG.
MDXG Stock Overview
| Market Cap in USD | 1,096m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2007-08-22 |
MDXG Stock Ratings
| Growth Rating | 15.7% |
| Fundamental | 79.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -14.9% |
| Analyst Rating | 5.0 of 5 |
MDXG Dividends
Currently no dividends paidMDXG Growth Ratios
| Growth Correlation 3m | -19.9% |
| Growth Correlation 12m | -67.5% |
| Growth Correlation 5y | -1.5% |
| CAGR 5y | 32.02% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.79 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.81 |
| Sharpe Ratio 12m | -0.88 |
| Alpha | -27.13 |
| Beta | 1.731 |
| Volatility | 42.08% |
| Current Volume | 1009.6k |
| Average Volume 20d | 560.1k |
| Stop Loss | 7 (-4.5%) |
| Signal | 1.10 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (40.8m TTM) > 0 and > 6% of Revenue (6% = 23.6m TTM) |
| FCFTA 0.21 (>2.0%) and ΔFCFTA -2.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 49.92% (prev 37.98%; Δ 11.94pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.21 (>3.0%) and CFO 67.8m > Net Income 40.8m (YES >=105%, WARN >=100%) |
| Net Debt (-140.7m) to EBITDA (68.6m) ratio: -2.05 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.41 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (149.7m) change vs 12m ago 0.90% (target <= -2.0% for YES) |
| Gross Margin 81.99% (prev 83.26%; Δ -1.27pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 139.8% (prev 140.6%; Δ -0.76pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 12.65 (EBITDA TTM 68.6m / Interest Expense TTM 4.27m) >= 6 (WARN >= 3) |
Altman Z'' 3.98
| (A) 0.62 = (Total Current Assets 254.1m - Total Current Liabilities 57.7m) / Total Assets 319.0m |
| (B) -0.18 = Retained Earnings (Balance) -57.9m / Total Assets 319.0m |
| (C) 0.19 = EBIT TTM 54.0m / Avg Total Assets 281.4m |
| (D) -0.72 = Book Value of Equity -57.7m / Total Liabilities 80.0m |
| Total Rating: 3.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 79.37
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 7.10% = 3.55 |
| 3. FCF Margin 17.24% = 4.31 |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda -2.05 = 2.50 |
| 6. ROIC - WACC (= 5.38)% = 6.72 |
| 7. RoE 19.18% = 1.60 |
| 8. Rev. Trend 89.68% = 6.73 |
| 9. EPS Trend 39.38% = 1.97 |
What is the price of MDXG shares?
Over the past week, the price has changed by -0.95%, over one month by +0.27%, over three months by +1.24% and over the past year by -2.27%.
Is MiMedx a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MDXG is around 6.31 USD . This means that MDXG is currently overvalued and has a potential downside of -13.92%.
Is MDXG a buy, sell or hold?
- Strong Buy: 5
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MDXG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12.2 | 66.4% |
| Analysts Target Price | 12.2 | 66.4% |
| ValueRay Target Price | 7.3 | -0.7% |
MDXG Fundamental Data Overview November 01, 2025
P/E Trailing = 27.4074
P/E Forward = 19.5313
P/S = 3.0127
P/B = 4.5831
P/EG = 2.97
Beta = 1.731
Revenue TTM = 393.4m USD
EBIT TTM = 54.0m USD
EBITDA TTM = 68.6m USD
Long Term Debt = 17.8m USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.38m USD (from shortTermDebt, last quarter)
Debt = 1.38m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -140.7m USD (from netDebt column, last quarter)
Enterprise Value = 955.2m USD (1.10b + Debt 1.38m - CCE 142.1m)
Interest Coverage Ratio = 12.65 (Ebit TTM 54.0m / Interest Expense TTM 4.27m)
FCF Yield = 7.10% (FCF TTM 67.8m / Enterprise Value 955.2m)
FCF Margin = 17.24% (FCF TTM 67.8m / Revenue TTM 393.4m)
Net Margin = 10.38% (Net Income TTM 40.8m / Revenue TTM 393.4m)
Gross Margin = 81.99% ((Revenue TTM 393.4m - Cost of Revenue TTM 70.9m) / Revenue TTM)
Gross Margin QoQ = 83.54% (prev 81.05%)
Tobins Q-Ratio = 2.99 (Enterprise Value 955.2m / Total Assets 319.0m)
Interest Expense / Debt = 57.09% (Interest Expense 785.0k / Debt 1.38m)
Taxrate = 26.70% (6.10m / 22.8m)
NOPAT = 39.6m (EBIT 54.0m * (1 - 26.70%))
Current Ratio = 4.41 (Total Current Assets 254.1m / Total Current Liabilities 57.7m)
Debt / Equity = 0.01 (Debt 1.38m / totalStockholderEquity, last quarter 238.9m)
Debt / EBITDA = -2.05 (Net Debt -140.7m / EBITDA 68.6m)
Debt / FCF = -2.07 (Net Debt -140.7m / FCF TTM 67.8m)
Total Stockholder Equity = 212.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.80% (Net Income 40.8m / Total Assets 319.0m)
RoE = 19.18% (Net Income TTM 40.8m / Total Stockholder Equity 212.9m)
RoCE = 23.39% (EBIT 54.0m / Capital Employed (Equity 212.9m + L.T.Debt 17.8m))
RoIC = 17.75% (NOPAT 39.6m / Invested Capital 222.8m)
WACC = 12.37% (E(1.10b)/V(1.10b) * Re(12.39%) + (debt cost/tax rate unavailable))
Discount Rate = 12.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.55%
[DCF Debug] Terminal Value 68.39% ; FCFE base≈63.9m ; Y1≈78.0m ; Y5≈129.8m
Fair Price DCF = 7.84 (DCF Value 1.16b / Shares Outstanding 148.1m; 5y FCF grow 23.54% → 3.0% )
EPS Correlation: 39.38 | EPS CAGR: 74.95% | SUE: 1.09 | # QB: 1
Revenue Correlation: 89.68 | Revenue CAGR: 16.70% | SUE: 4.0 | # QB: 2
Additional Sources for MDXG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle